Mini and enhanced CRISPR activators for cancer therapies
Related Experiment Video
Updated: Jun 8, 2025
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
Meiyu Huang1, Keshan Wang2, Anshu Li3
1College of Life Sciences, Guangxi Normal University, Guilin, China.
Introduction:
The RNA-guided nuclease Cas9 can be used as a programmable transcription activator, but there is still room for improvement in its effectiveness in eukaryotes, and its potential in cancer genetic therapy has been poorly investigated.
Objectives:
We aim to construct optimized CRISPRa tools and detect their potential role in cancer therapy by screening 9aa-TAD.
Methods:
We selected a range of transcriptional coactivators for programmable activation and analyzed their effects on the expression of multiple endogenous genes using Flow cytometry and qRT-PCR. In order to improve the activation capacity of the CRISPRa tool, we fused the coactivators with the efficient dCas9-VPR system to construct a new activation system. Utilize RNA-seq to assess the activation specificity of genome-wide. To evaluate the value of the newly constructed activation system in cancer gene therapy, we activated the expression of the tumor suppressor genes PER2 and ZNF382, and performed changes in cancer cell proliferation qRT-PCR and clonal formation analysis.
Results:
In this study, we screened the NHR module from C. elegans, which demonstrated a high transcription activation capacity with a compact size compared to VP64. We successfully demonstrated its efficiency in activating endogenous genes in mammalian cells. Furthermore, we developed an enhanced fused variant called NHR-VP64-p65-Rta (NVPR), which showed even higher efficiency compared to the previously established VPR module, making it an effective CRISPRa tool. The dCas9-NVPR complex also exhibited high specificity on a genome-wide scale. Finally, we utilized the dCas9-NVPR tool to restore the expression of tumor suppressor genes PER2 and ZNF382, effectively inhibiting the malignant phenotype of cancer cells.
Conclusion:
We have successfully developed and demonstrated a breakthrough CRISPRa tool with promising implications for cancer genetic therapy. This innovation expands the range of available gene editing tools and further validates the immense potential of CRISPR-based approaches in precision medicine.
Insights
Researchers developed a novel CRISPR activation (CRISPRa) tool, dCas9-NVPR, demonstrating enhanced gene activation and specificity. This tool effectively inhibited cancer cell proliferation by restoring tumor suppressor gene expression, showing promise for cancer gene therapy.
Area of Science:
- Molecular Biology
- Gene Editing
- Cancer Research
Background:
- CRISPR-Cas9 is a programmable transcription activator with potential in eukaryotes.
- Existing CRISPR activation (CRISPRa) tools require optimization for enhanced effectiveness.
- The application of CRISPRa in cancer genetic therapy remains underexplored.
Purpose of the Study:
- To construct optimized CRISPRa tools by screening transcriptional coactivators.
- To evaluate the efficacy of novel CRISPRa systems in activating endogenous genes.
- To assess the potential of CRISPRa in cancer gene therapy by targeting tumor suppressor genes.
Main Methods:
- Screening of transcriptional coactivators and fusion with dCas9-VPR system.
- Analysis of gene expression using Flow cytometry and qRT-PCR.
- Genome-wide specificity assessment using RNA-seq.
- Evaluation of cancer cell proliferation and clonal formation after gene activation.
Main Results:
- Identified NHR module from C. elegans with high transcription activation capacity.
- Developed enhanced CRISPRa tool dCas9-NVPR, outperforming existing VPR module.
- Demonstrated high specificity of dCas9-NVPR on a genome-wide scale.
- Successfully restored expression of tumor suppressor genes PER2 and ZNF382, inhibiting cancer cell malignancy.
Conclusions:
- Developed a breakthrough CRISPRa tool, dCas9-NVPR, with enhanced efficiency and specificity.
- Validated the potential of CRISPRa for cancer genetic therapy by targeting tumor suppressor genes.
- Expanded the toolkit for gene editing and reinforced the promise of CRISPR-based precision medicine.
Related Concept Videos
01:59CRISPR
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:31Homologous Recombination
02:53CRISPR and crRNAs
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
02:53Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...